TLR agonists can promote Th1(T helper) mediated inflammatory responses and activate APCs in the TME, facilitating tumor infiltration as well as improved functioning of the effector immune cells, like CD8+ T cells and NK cells (212). Here, CD8A is linked to neoplasm.